secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001178253-25-000006
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment
---------------------------------------------------------------------

- Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.
- Additional $2.3M payment from GSK for wind-down and termination activities.
- SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.
- Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/0001178253-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000117825325000006/scyx-20251014.htm
  HTML page:      https://secwatch.observer/filing/0001178253-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer